# Filing Detail

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-24-021253
Filing Date
2024-02-27
Accepted
2024-02-27 16:33:19
Documents
98
Period of Report
2023-12-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-K | sndx-20231231.htm iXBRL | 10-K | 2833776
2 | EX-4.3 | sndx-ex4_3.htm | EX-4.3 | 29773
3 | EX-10.16 | sndx-ex10_16.htm | EX-10.16 | 347385
4 | EX-10.20 | sndx-ex10_20.htm | EX-10.20 | 28142
5 | EX-10.22 | sndx-ex10_22.htm | EX-10.22 | 238614
6 | EX-10.23 | sndx-ex10_23.htm | EX-10.23 | 28135
7 | EX-10.25 | sndx-ex10_25.htm | EX-10.25 | 27839
8 | EX-10.27 | sndx-ex10_27.htm | EX-10.27 | 27816
9 | EX-10.30 | sndx-ex10_30.htm | EX-10.30 | 27870
10 | EX-10.31 | sndx-ex10_31.htm | EX-10.31 | 14712
11 | EX-23.1 | sndx-ex23_1.htm | EX-23.1 | 4353
12 | EX-31.1 | sndx-ex31_1.htm | EX-31.1 | 13970
13 | EX-31.2 | sndx-ex31_2.htm | EX-31.2 | 13955
14 | EX-32.1 | sndx-ex32_1.htm | EX-32.1 | 13880
15 | EX-97 | sndx-ex97.htm | EX-97 | 51646
16 | GRAPHIC | img207175068_0.jpg | GRAPHIC | 251916
17 | GRAPHIC | img207175068_1.jpg | GRAPHIC | 123912
18 | GRAPHIC | img207175068_2.jpg | GRAPHIC | 54373
19 | GRAPHIC | img207175068_3.jpg | GRAPHIC | 90642
20 | GRAPHIC | img207175068_4.jpg | GRAPHIC | 54075
| Complete submission text file | 0000950170-24-021253.txt |  | 12877333

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
21 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | sndx-20231231.xsd | EX-101.SCH | 1683236
100 | EXTRACTED XBRL INSTANCE DOCUMENT | sndx-20231231_htm.xml | XML | 1614923

Mailing Address 35 GATEHOUSE DRIVE BUILDING D, FLOOR 3 WALTHAM MA 02451
Business Address 35 GATEHOUSE DRIVE BUILDING D, FLOOR 3 WALTHAM MA 02451 781-419-1400
Syndax Pharmaceuticals Inc (Filer) CIK: 0001395937 (see all company filings)

EIN.: 320162505 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-37708 | Film No.: 24687479
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)